REFERENCES
1. Cresswell JA, Alexander M, Chong MYC, et al. Global and regional causes of maternal deaths 2009-20: a WHO systematic analysis. Lancet Glob Health. 2025;13:e626-34.
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
3. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
4. Witwer KW, Théry C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. J Extracell Vesicles. 2019;8:1648167.
5. Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75:193-208.
6. Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. N Engl J Med. 2018;379:958-66.
7. Bjørge IM, Kim SY, Mano JF, Kalionis B, Chrzanowski W. Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine - a new paradigm for tissue repair. Biomater Sci. 2017;6:60-78.
8. van Niel G, Carter DRF, Clayton A, Lambert DW, Raposo G, Vader P. Challenges and directions in studying cell-cell communication by extracellular vesicles. Nat Rev Mol Cell Biol. 2022;23:369-82.
9. Zhao Z, Moley KH, Gronowski AM. Diagnostic potential for miRNAs as biomarkers for pregnancy-specific diseases. Clin Biochem. 2013;46:953-60.
10. Manna S, McCarthy C, McCarthy FP. Placental ageing in adverse pregnancy outcomes: telomere shortening, cell senescence, and mitochondrial dysfunction. Oxid Med Cell Longev. 2019;2019:3095383.
11. Martin C, Bergamelli M, Malnou CE, D’Angelo G. Placental extracellular vesicles in maternal-fetal communication during pregnancy. Biochem Soc Trans. 2022;50:1785-95.
12. Cui J, Yang Z, Ma R, et al. Placenta-targeted treatment strategies for preeclampsia and fetal growth restriction: an opportunity and major challenge. Stem Cell Rev Rep. 2024;20:1501-11.
13. Chang X, He Q, Wei M, et al. Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia. Eur J Med Res. 2023;28:277.
14. Zheng S, Shi A, Hill S, et al. Decidual mesenchymal stem/stromal cell-derived extracellular vesicles ameliorate endothelial cell proliferation, inflammation, and oxidative stress in a cell culture model of preeclampsia. Pregnancy Hypertens. 2020;22:37-46.
15. Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008;26:300-11.
16. Silini AR, Di Pietro R, Lang-Olip I, et al. Perinatal derivatives: where do we stand? A roadmap of the human placenta and consensus for tissue and cell nomenclature. Front Bioeng Biotechnol. 2020;8:610544.
17. Kulubya ES, Clark K, Hao D, et al. The unique properties of placental mesenchymal stromal cells: a novel source of therapy for congenital and acquired spinal cord injury. Cells. 2021;10:2837.
18. Chen Z, Xia X, Yao M, et al. The dual role of mesenchymal stem cells in apoptosis regulation. Cell Death Dis. 2024;15:250.
19. Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: clinical trial update and perspectives. J Orthop Translat. 2017;9:76-88.
20. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014;2:606-19.
21. Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148-69.
22. Robillard PY, Dekker G, Scioscia M, et al. Validation of the 34-week gestation as definition of late onset preeclampsia: testing different cutoffs from 30 to 37 weeks on a population-based cohort of 1700 preeclamptics. Acta Obstet Gynecol Scand. 2020;99:1181-90.
23. Karumanchi SA, Lindheimer MD. Advances in the understanding of eclampsia. Curr Hypertens Rep. 2008;10:305-12.
24. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016;387:999-1011.
27. Sultana Z, Maiti K, Dedman L, Smith R. Is there a role for placental senescence in the genesis of obstetric complications and fetal growth restriction? Am J Obstet Gynecol. 2018;218:S762-73.
28. Murthi P, Brennecke SP. The placenta is the villain or victim in the pathogenesis of pre-eclampsia: FOR: the placenta is the villain in the pathogenesis of preeclampsia. BJOG. 2021;128:147.
29. Cui Y, Zhu B, Zheng F. Low-dose aspirin at ≤ 16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: a systematic review and meta-analysis. Exp Ther Med. 2018;15:4361-9.
30. Roberge S, Bujold E, Nicolaides KH. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol. 2018;218:483-9.
31. Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114:289-99.
32. Pourakbari R, Parhizkar F, Soltani-Zangbar MS, et al. Preeclampsia-derived exosomes imbalance the activity of Th17 and treg in PBMCs from healthy pregnant women. Reprod Sci. 2023;30:1186-97.
33. Mikhailova VA, Ovchinnikova OM, Zainulina MS, Sokolov DI, Sel’kov SA. Detection of microparticles of leukocytic origin in the peripheral blood in normal pregnancy and preeclampsia. Bull Exp Biol Med. 2014;157:751-6.
34. Tannetta DS, Hunt K, Jones CI, et al. Syncytiotrophoblast extracellular vesicles from pre-eclampsia placentas differentially affect platelet function. PLoS One. 2015;10:e0142538.
35. Motta-Mejia C, Kandzija N, Zhang W, et al. Placental vesicles carry active endothelial nitric oxide synthase and their activity is reduced in preeclampsia. Hypertension. 2017;70:372-81.
36. Powell JS, Gandley RE, Lackner E, et al. Small extracellular vesicles from plasma of women with preeclampsia increase myogenic tone and decrease endothelium-dependent relaxation of mouse mesenteric arteries. Pregnancy Hypertens. 2022;28:66-73.
37. Dutta S, Lai A, Scholz-Romero K, et al. Hypoxia-induced small extracellular vesicle proteins regulate proinflammatory cytokines and systemic blood pressure in pregnant rats. Clin Sci. 2020;134:593-607.
38. Wang Y, Du X, Wang J. Transfer of miR-15a-5p by placental exosomes promotes pre-eclampsia progression by regulating PI3K/AKT signaling pathway via CDK1. Mol Immunol. 2020;128:277-86.
39. Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol. 2002;187:1686-93.
40. Shomer E, Katzenell S, Zipori Y, et al. Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension. 2013;62:893-8.
41. Han C, Wang C, Chen Y, et al. Placenta-derived extracellular vesicles induce preeclampsia in mouse models. Haematologica. 2020;105:1686-94.
42. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-9.
43. Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13:17-24.
44. Liu XM, Halushka MK. Beyond the bubble: a debate on microRNA sorting into extracellular vesicles. Lab Invest. 2025;105:102206.
45. Wallis R, Mizen H, Bishop CL. The bright and dark side of extracellular vesicles in the senescence-associated secretory phenotype. Mech Ageing Dev. 2020;189:111263.
46. Chen Z, Wu M, Huang H, Tao H, Zou L, Luo Q. Plasma exosomal miR-199a-5p derived from preeclampsia with severe features impairs endothelial cell function via targeting SIRT1. Reprod Sci. 2022;29:3413-24.
47. Chen Z, Wu M, Huang H, Tao H, Zou L, Luo Q. Correction: plasma exosomal miR-199a-5p derived from preeclampsia with severe features impairs endothelial cell function via targeting SIRT1. Reprod Sci. 2024;31:579.
48. Bakrania BA, George EM, Granger JP. Animal models of preeclampsia: investigating pathophysiology and therapeutic targets. Am J Obstet Gynecol. 2022;226:S973-87.
49. Woolston E, Tang Y, Azizi S, et al. Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia. J Hum Hypertens. 2022;36:192-200.
50. Santoyo JM, Noguera JA, Avilés F, et al. Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia. Front Pharmacol. 2023;14:1166123.
51. Sarker S, Scholz-Romero K, Perez A, et al. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12:204.
52. Salomon C, Guanzon D, Scholz-Romero K, et al. Placental exosomes as early biomarker of preeclampsia: potential role of exosomal MicroRNAs across gestation. J Clin Endocrinol Metab. 2017;102:3182-94.
53. Palma C, Masud MK, Guanzon D, et al. Rapid and high-sensitivity screening of pregnancy complications by profiling circulating placental extracellular vesicles. Sci Adv. 2025;11:eadr4074.
54. Popova AK, Vashukova ES, Illarionov RA, et al. Extracellular vesicles as biomarkers of pregnancy complications. Int J Mol Sci. 2024;25:11944.
55. Barnes MVC, Pantazi P, Holder B. Circulating extracellular vesicles in healthy and pathological pregnancies: a scoping review of methodology, rigour and results. J Extracell Vesicles. 2023;12:e12377.
56. Yu Z, Zhang W, Wang Y, et al. Extracellular vesicles derived from human umbilical cord MSC improve vascular endothelial function in in vitro and in vivo models of preeclampsia through activating arginine metabolism. Mol Pharm. 2023;20:6429-40.
57. Xiong ZH, Wei J, Lu MQ, Jin MY, Geng HL. Protective effect of human umbilical cord mesenchymal stem cell exosomes on preserving the morphology and angiogenesis of placenta in rats with preeclampsia. Biomed Pharmacother. 2018;105:1240-7.
58. Taglauer ES, Fernandez-Gonzalez A, Willis GR, et al. Mesenchymal stromal cell-derived extracellular vesicle therapy prevents preeclamptic physiology through intrauterine immunomodulation†. Biol Reprod. 2021;104:457-67.
59. Taglauer ES, Fernandez-Gonzalez A, Willis GR, et al. Antenatal mesenchymal stromal cell extracellular vesicle therapy prevents preeclamptic lung injury in mice. Am J Respir Cell Mol Biol. 2022;66:86-95.
60. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26:1474-83.
61. Jiang Y, Luo T, Xia Q, Tian J, Yang J. microRNA-140-5p from human umbilical cord mesenchymal stem cells-released exosomes suppresses preeclampsia development. Funct Integr Genomics. 2022;22:813-24.
62. Chen Y, Zhou C, Zhao X, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells promote trophoblast cell proliferation and migration by targeting TFPI2 in preeclampsia. Stem Cells Int. 2023;2023:7927747.
63. Yang Z, Shan N, Deng Q, et al. Extracellular vesicle-derived microRNA-18b ameliorates preeclampsia by enhancing trophoblast proliferation and migration via Notch2/TIM3/mTORC1 axis. J Cell Mol Med. 2021;25:4583-95.
64. College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics and the Society for Maternal-Fetal Medicine. ACOG practice bulletin No. 204: fetal growth restriction. Obstet Gynecol. 2019;133:e97-109.
65. Dall’Asta A, Brunelli V, Prefumo F, Frusca T, Lees CC. Early onset fetal growth restriction. Matern Health Neonatol Perinatol. 2017;3:2.
66. Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36:86-98.
67. Audette MC, Kingdom JC. Screening for fetal growth restriction and placental insufficiency. Semin Fetal Neonatal Med. 2018;23:119-25.
68. Ghidini A. Idiopathic fetal growth restriction: a pathophysiologic approach. Obstet Gynecol Surv. 1996;51:376-82.
69. Giabicani E, Pham A, Brioude F, Mitanchez D, Netchine I. Diagnosis and management of postnatal fetal growth restriction. Best Pract Res Clin Endocrinol Metab. 2018;32:523-34.
70. Fantasia I, Zamagni G, Lees C, et al. Current practice in the diagnosis and management of fetal growth restriction: an international survey. Acta Obstet Gynecol Scand. 2022;101:1431-9.
71. Colella M, Frérot A, Novais ARB, Baud O. Neonatal and long-term consequences of fetal growth restriction. Curr Pediatr Rev. 2018;14:212-8.
72. Kesavan K, Devaskar SU. Intrauterine growth restriction: postnatal monitoring and outcomes. Pediatr Clin North Am. 2019;66:403-23.
73. McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018;218:S855-68.
74. Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218:S829-40.
75. Luo J, Fan Y, Shen L, et al. The pro-angiogenesis of exosomes derived from umbilical cord blood of intrauterine growth restriction pigs was repressed associated with miRNAs. Int J Biol Sci. 2018;14:1426-36.
76. Tavanasefat H, Li F, Koyano K, et al. Molecular consequences of fetal alcohol exposure on amniotic exosomal miRNAs with functional implications for stem cell potency and differentiation. PLoS One. 2020;15:e0242276.
77. Ariyakumar G, Morris JM, McKelvey KJ, Ashton AW, McCracken SA. NF-κB regulation in maternal immunity during normal and IUGR pregnancies. Sci Rep. 2021;11:20971.
78. WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand. 1977;56:247-53.
79. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162-72.
80. Di Renzo GC, Tosto V, Giardina I. The biological basis and prevention of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:13-22.
81. Frey HA, Klebanoff MA. The epidemiology, etiology, and costs of preterm birth. Semin Fetal Neonatal Med. 2016;21:68-73.
82. Vogel JP, Chawanpaiboon S, Moller AB, Watananirun K, Bonet M, Lumbiganon P. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:3-12.
83. Ibrahim MH, Elfaki T, Elhassan EM, Abdelrahiem SK, Adam I. The effectiveness of nifedipine/indomethacin combination therapy and nifedipine monotherapy for postponing preterm birth (25-34 weeks of gestation) in Sudanese women: a randomized clinical trial study protocol. BMC Pregnancy Childbirth. 2021;21:457.
85. Liu L, Johnson HL, Cousens S, et al; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379:2151-61.
86. Monsivais LA, Sheller-Miller S, Russell W, et al. Fetal membrane extracellular vesicle profiling reveals distinct pathways induced by infection and inflammation in vitro. Am J Reprod Immunol. 2020;84:e13282.
87. Tiozzo C, Bustoros M, Lin X, et al. Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy. Am J Obstet Gynecol. 2021;225:681.e1-20.
88. Willis GR, Kourembanas S, Mitsialis SA. Therapeutic applications of extracellular vesicles: perspectives from newborn medicine. Methods Mol Biol. 2017;1660:409-32.
89. Fernandez-Gonzalez A, Willis GR, Yeung V, et al. Therapeutic effects of mesenchymal stromal cell-derived small extracellular vesicles in oxygen-induced multi-organ disease: a developmental perspective. Front Cell Dev Biol. 2021;9:647025.
90. Lesage F, Thébaud B. Nanotherapies for micropreemies: stem cells and the secretome in bronchopulmonary dysplasia. Semin Perinatol. 2018;42:453-8.
91. Lee C, Mitsialis SA, Aslam M, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012;126:2601-11.
92. Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197:104-16.
93. Thomi G, Joerger-Messerli M, Haesler V, Muri L, Surbek D, Schoeberlein A. Intranasally administered exosomes from umbilical cord stem cells have preventive neuroprotective effects and contribute to functional recovery after perinatal brain injury. Cells. 2019;8:855.
94. Thomi G, Surbek D, Haesler V, Joerger-Messerli M, Schoeberlein A. Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem Cell Res Ther. 2019;10:105.
95. Yang C, Lim W, Park J, Park S, You S, Song G. Anti-inflammatory effects of mesenchymal stem cell-derived exosomal microRNA-146a-5p and microRNA-548e-5p on human trophoblast cells. Mol Hum Reprod. 2019;25:755-71.
96. Nakshine VS, Jogdand SD. A comprehensive review of gestational diabetes mellitus: impacts on maternal health, fetal development, childhood outcomes, and long-term treatment strategies. Cureus. 2023;15:e47500.
97. Fu J, Retnakaran R. The life course perspective of gestational diabetes: an opportunity for the prevention of diabetes and heart disease in women. EClinicalMedicine. 2022;45:101294.
98. Moore K, Stotz S, Fischl A, et al. Pregnancy and gestational diabetes mellitus (GDM) in North American Indian adolescents and young adults (AYA): implications for girls and stopping GDM. Curr Diab Rep. 2019;19:113.
99. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19:3342.
100. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019;5:47.
101. McElwain CJ, Tuboly E, McCarthy FP, McCarthy CM. Mechanisms of endothelial dysfunction in pre-eclampsia and gestational diabetes mellitus: windows into future cardiometabolic health? Front Endocrinol. 2020;11:655.
102. Ukke GG, Boyle JA, Reja A, et al. Lifestyle interventions to prevent type 2 diabetes in women with a history of gestational diabetes: a systematic review and meta-analysis through the lens of health equity. Nutrients. 2023;15:4666.
103. Diniz MS, Hiden U, Falcão-Pires I, Oliveira PJ, Sobrevia L, Pereira SP. Fetoplacental endothelial dysfunction in gestational diabetes mellitus and maternal obesity: a potential threat for programming cardiovascular disease. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166834.
104. Sáez T, de Vos P, Kuipers J, Sobrevia L, Faas MM. Fetoplacental endothelial exosomes modulate high d-glucose-induced endothelial dysfunction. Placenta. 2018;66:26-35.
105. James-Allan LB, Devaskar SU. Extracellular vesicles and their role in gestational diabetes mellitus. Placenta. 2021;113:15-22.
106. Jayabalan N, Lai A, Ormazabal V, et al. Adipose tissue exosomal proteomic profile reveals a role on placenta glucose metabolism in gestational diabetes mellitus. J Clin Endocrinol Metab. 2019;104:1735-52.
107. Kandzija N, Zhang W, Motta-Mejia C, et al. Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus. J Extracell Vesicles. 2019;8:1617000.
108. Salomon C, Scholz-Romero K, Sarker S, et al. Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. Diabetes. 2016;65:598-609.
109. Sáez T, Salsoso R, Leiva A, et al. Human umbilical vein endothelium-derived exosomes play a role in foetoplacental endothelial dysfunction in gestational diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2018;1864:499-508.
110. Kereliuk SM, Xiao F, Burger D, Dolinsky VW. Extracellular vesicles as an index for endothelial injury and cardiac dysfunction in a rodent model of GDM. Int J Mol Sci. 2022;23:4970.
111. James-Allan LB, Rosario FJ, Barner K, et al. Regulation of glucose homeostasis by small extracellular vesicles in normal pregnancy and in gestational diabetes. FASEB J. 2020;34:5724-39.
112. Bathla T, Abolbaghaei A, Reyes AB, Burger D. Extracellular vesicles in gestational diabetes mellitus: a scoping review. Diab Vasc Dis Res. 2022;19:14791641221093901.
113. Nair S, Jayabalan N, Guanzon D, et al. Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity. Clin Sci. 2018;132:2451-67.
114. Gao Z, Wang N, Liu X. Human placenta mesenchymal stem cell-derived exosome shuttling microRNA-130b-3p from gestational diabetes mellitus patients targets ICAM-1 and perturbs human umbilical vein endothelial cell angiogenesis. Acta Diabetol. 2022;59:1091-107.
115. Silverberg O, Park AL, Cohen E, Fell DB, Ray JG. Premature cardiac disease and death in women whose infant was preterm and small for gestational age: a retrospective cohort study. JAMA Cardiol. 2018;3:247-51.
116. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326:845.
117. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797-803.
118. Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-term cardiovascular risks associated with adverse pregnancy outcomes: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2106-16.
119. Behrens I, Basit S, Melbye M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078.
120. Lewey J, Beckie TM, Brown HL, et al; American Heart Association Cardiovascular Disease and Stroke in Women and Underrepresented Populations Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular and Stroke Nursing. Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: a scientific statement from the American heart association. Circulation 2024;149:e330-46.
121. Stanhewicz AE, Jandu S, Santhanam L, Alexander LM. Increased angiotensin II sensitivity contributes to microvascular dysfunction in women who have had preeclampsia. Hypertension. 2017;70:382-9.
122. Stanhewicz AE, Jandu S, Santhanam L, Alexander LM. Alterations in endothelin type B receptor contribute to microvascular dysfunction in women who have had preeclampsia. Clin Sci. 2017;131:2777-89.
123. Feng Y, Lau S, Chen Q, et al. Normotensive placental extracellular vesicles provide long-term protection against hypertension and cardiovascular disease. Am J Obstet Gynecol. 2024;231:350.e1-24.
124. Fuhrmann G, Lehr CM, Schiffelers R. Themed issue: extracellular vesicles in drug delivery and bioengineering. Adv Drug Deliv Rev. 2022;181:114073.
125. Sadeghi S, Tehrani FR, Tahmasebi S, Shafiee A, Hashemi SM. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023;31:145-69.
126. de Abreu RC, Fernandes H, da Costa Martins PA, Sahoo S, Emanueli C, Ferreira L. Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat Rev Cardiol. 2020;17:685-97.
127. Kusuma GD, Brennecke SP, O’Connor AJ, Kalionis B, Heath DE. Decellularized extracellular matrices produced from immortal cell lines derived from different parts of the placenta support primary mesenchymal stem cell expansion. PLoS One. 2017;12:e0171488.
128. Shakouri-Motlagh A, O’Connor AJ, Kalionis B, Heath DE. Improved ex vivo expansion of mesenchymal stem cells on solubilized acellular fetal membranes. J Biomed Mater Res A. 2019;107:232-42.
129. Yang MC, O’Connor AJ, Kalionis B, Heath DE. Improvement of mesenchymal stromal cell proliferation and differentiation via decellularized extracellular matrix on substrates with a range of surface chemistries. Front Med Technol. 2022;4:834123.
130. Luo ZW, Li FX, Liu YW, et al. Aptamer-functionalized exosomes from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale. 2019;11:20884-92.
131. Bose RJ, Kumar US, Garcia-Marques F, et al. Engineered cell-derived vesicles displaying targeting peptide and functionalized with nanocarriers for therapeutic microRNA delivery to triple-negative breast cancer in mice. Adv Healthc Mater. 2022;11:e2101387.
132. Sheller-Miller S, Radnaa E, Yoo JK, et al. Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models. Sci Adv. 2021;7:eabd3865.
133. Kammala AK, Mosebarger A, Radnaa E, et al. Extracellular vesicles-mediated recombinant IL-10 protects against ascending infection-associated preterm birth by reducing fetal inflammatory response. Front Immunol. 2023;14:1196453.
134. Ducrot C, Loiseau S, Wong C, Madec E, Volatron J, Piffoux M. Hybrid extracellular vesicles for drug delivery. Cancer Lett. 2023;558:216107.
135. Sherman CD, Lodha S, Sahoo S. EV cargo sorting in therapeutic development for cardiovascular disease. Cells. 2021;10:1500.
136. Qin SQ, Kusuma GD, Al-Sowayan B, et al. Establishment and characterization of fetal and maternal mesenchymal stem/stromal cell lines from the human term placenta. Placenta. 2016;39:134-46.
137. Khanabdali R, Shojaee M, Johnson J, et al. Profiling the extracellular vesicles of two human placenta-derived mesenchymal stromal cell populations. Exp Cell Res. 2025;444:114387.
138. Lu CH, Chen YA, Ke CC, Liu RS. Mesenchymal stem cell-derived extracellular vesicle: a promising alternative therapy for osteoporosis. Int J Mol Sci. 2021;22:12750.
139. Nieuwland R, Siljander PR, Falcón-Pérez JM, Witwer KW. Reproducibility of extracellular vesicle research. Eur J Cell Biol. 2022;101:151226.
140. Kusuma GD, Abumaree MH, Pertile MD, Kalionis B. Isolation and characterization of mesenchymal stem/stromal cells derived from human third trimester placental chorionic villi and decidua basalis. Methods Mol Biol. 2018;1710:247-66.
141. Ross M, Jadli AS, Meechem M, Patel VB. Isolation and characterization of extracellular vesicles from cell culture media. Methods Mol Biol. 2024;2835:165-72.
142. Sharma S, Scholz-Romero K, Rice GE, Salomon C. Methods to enrich exosomes from conditioned media and biological fluids. Methods Mol Biol. 2018;1710:103-15.
143. Williams S, Fernandez-Rhodes M, Law A, Peacock B, Lewis MP, Davies OG. Comparison of extracellular vesicle isolation processes for therapeutic applications. J Tissue Eng. 2023;14:20417314231174609.
144. Bağcı C, Sever-Bahcekapili M, Belder N, Bennett APS, Erdener ŞE, Dalkara T. Overview of extracellular vesicle characterization techniques and introduction to combined reflectance and fluorescence confocal microscopy to distinguish extracellular vesicle subpopulations. Neurophotonics. 2022;9:021903.
145. Welsh JA, Goberdhan DCI, O’Driscoll L, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
146. Wang Z, Zhou X, Kong Q, et al. Extracellular vesicle preparation and analysis: a state-of-the-art review. Adv Sci. 2024;11:e2401069.
147. De Sousa KP, Rossi I, Abdullahi M, Ramirez MI, Stratton D, Inal JM. Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15:e1835.
148. Kim SY, Khanal D, Tharkar P, Kalionis B, Chrzanowski W. None of us is the same as all of us: resolving the heterogeneity of extracellular vesicles using single-vesicle, nanoscale characterization with resonance enhanced atomic force microscope infrared spectroscopy (AFM-IR). Nanoscale Horiz. 2018;3:430-8.
149. Kobayashi H, Shiba T, Yoshida T, et al. Precise analysis of single small extracellular vesicles using flow cytometry. Sci Rep. 2024;14:7465.
150. Zhang S, Deng J, Li J, et al. Advanced microfluidic technologies for isolating extracellular vesicles. TrAC Trends in Analytical Chemistry. 2022;157:116817.
151. Nguyen CM, Sallam M, Islam MS, et al. Placental exosomes as biomarkers for maternal diseases: current advances in isolation, characterization, and detection. ACS Sens. 2023;8:2493-513.
152. Clack K, Soda N, Kasetsirikul S, Mahmudunnabi RG, Nguyen NT, Shiddiky MJA. Toward personalized nanomedicine: the critical evaluation of micro and nanodevices for cancer biomarker analysis in liquid biopsy. Small. 2023;19:e2205856.
153. Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev. 2021;178:113961.
154. Syromiatnikova V, Prokopeva A, Gomzikova M. Methods of the large-scale production of extracellular vesicles. Int J Mol Sci. 2022;23:10522.
155. Chau K, Welsh M, Makris A, Hennessy A. Progress in preeclampsia: the contribution of animal models. J Hum Hypertens. 2022;36:705-10.
156. Aguilera N, Salas-Pérez F, Ortíz M, Álvarez D, Echiburú B, Maliqueo M. Rodent models in placental research. Implications for fetal origins of adult disease. Anim Reprod. 2022;19:e20210134.
157. Barry JS, Anthony RV. The pregnant sheep as a model for human pregnancy. Theriogenology. 2008;69:55-67.
158. Carter AM. Animal models of human pregnancy and placentation: alternatives to the mouse. Reproduction. 2020;160:R129-43.
159. Nguyen D, Xu T. The expanding role of mouse genetics for understanding human biology and disease. Dis Model Mech. 2008;1:56-66.
160. Menon R, Richardson L, Kammala AK. New approach methods on the bench side to accelerate clinical trials during pregnancy. Expert Opin Drug Metab Toxicol. 2024;20:555-60.
161. Tong M, Stanley JL, Chen Q, James JL, Stone PR, Chamley LW. Placental nano-vesicles target to specific organs and modulate vascular tone in vivo. Hum Reprod. 2017;32:2188-98.
162. Ganguly E, Hula N, Spaans F, Cooke CM, Davidge ST. Placenta-targeted treatment strategies: an opportunity to impact fetal development and improve offspring health later in life. Pharmacol Res. 2020;157:104836.
163. Wilson RL, Jones HN. Targeting the dysfunctional placenta to improve pregnancy outcomes based on lessons learned in cancer. Clin Ther. 2021;43:246-64.
164. Pepe GJ, Albrecht ED. Novel technologies for target delivery of therapeutics to the placenta during pregnancy: a review. Genes. 2021;12:1255.
